Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)273 enrolled

Overview

This protocol concerns the approach to the localization, diagnosis of MEN1 and management of the tumor and the tissue samples in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor, investigations for MEN1 the subsequent management of the tumor and tissue samples for research....

This protocol concerns the approach to the localization and management of the tumor in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor and the subsequent management of the tumor.

Study Type

OBSERVATIONAL

Enrollment

273

Conditions

Zollinger Ellison Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

* INCLUSION CRITERIA: New patients will be evaluated initially as described in the protocol entitled, "Diagnostic evaluation of patients with suspected abnormalities of gastric secretion" (89-DK-0005). Only those patients that are being treated under the protocol entitled, "Medical Therapy of Zollinger-Ellison Syndrome" (protocol # 89-DK-0015) will be entered into this tumor localization and management protocol.

Locations (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

To determine an approach to the localization and management of tumor in patients with ZES.

localization of tumor

Time frame: Yearly

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.